Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Fort Worth, Texas. The company focuses on developing therapies for difficult-to-treat cancers by targeting biological pathways that promote tumor growth and resistance. Its lead product candidate, elraglusib, is a small-molecule inhibitor currently in clinical trials for metastatic pancreatic cancer and various pediatric malignancies.
Actuate Therapeutics is a pre-revenue, clinical-stage biopharmaceutical company with no products approved for sale and no product revenue to date; accordingly, it has no commercial customers or customer concentration.